Phenotypes Associated with This Genotype

Genotype
MGI:5908356

• Allelic Composition: Tg(Myh6-EGFR*)9-12Iko/0
• Genetic Background: involves: C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:182337 )

• mice exhibit non-ischemic heart failure and die at 5-30 weeks of age

cardiovascular system

increased heart weight ( J:182337 )

• the heart/body weight ratio is about 1.5-fold higher at 6 weeks of age

dilated heart ( J:182337 )

• global chamber dilatation with marked wall thinning

dilated cardiomyopathy ( J:182337 )

• mice develop non-ischemic dilated cardiomyopathy

decreased cardiac muscle contractility ( J:182337 )

• mice exhibit decreased fractional shortening

• 8 week old mice intravenously infused with wild-type bone marrow-derived mononuclear cells (BMMNC) show improved fractional shortening 3 days after infusion, however this effect is lost by 14 days after infusion

• BMMNC infusion repeated every 2 weeks results in improved cardiac function for more than 50 days

• mice injected intraperitoneally for 2 weeks with an anti-activin A antibody show improved fractional shortening and +dp/dt

abnormal heart echocardiography feature ( J:182337 )

• echocardiography indicates a decrease in fractional shortening together with chamber dilatation

congestive heart failure ( J:182337 )

• mice succumb to non-ischemic heart failure

homeostasis/metabolism

abnormal blood homeostasis ( J:182337 )

• serum activin A levels are increased

decreased growth hormone level ( J:182337 )

• decrease in growth hormone concentration in serum

muscle

dilated cardiomyopathy ( J:182337 )

• mice develop non-ischemic dilated cardiomyopathy

decreased cardiac muscle contractility ( J:182337 )

• mice exhibit decreased fractional shortening

• 8 week old mice intravenously infused with wild-type bone marrow-derived mononuclear cells (BMMNC) show improved fractional shortening 3 days after infusion, however this effect is lost by 14 days after infusion

• BMMNC infusion repeated every 2 weeks results in improved cardiac function for more than 50 days

• mice injected intraperitoneally for 2 weeks with an anti-activin A antibody show improved fractional shortening and +dp/dt

growth/size/body

increased heart weight ( J:182337 )

• the heart/body weight ratio is about 1.5-fold higher at 6 weeks of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
dilated cardiomyopathy		DOID:12930	OMIM:PS115200	J:182337